AUPH
Aurinia Pharmaceuticals Inc.
Next earnings Jul 29, 2026 · consensus $0.25 EPS, $81.3M rev
Last earnings -6.8% on 2026-05-07
$17.23
▼ -1.82%$17.23▲ +120.05%
over 1Y
L $7.47EODHDH $18.62
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.8%
1W-1.7%
1M+10.9%
3M+20.7%
YTD+12.2%
1Y+120.1%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Revenue grew 20.4% YoY.
Revenue (FY2025) $283M · FY2025
The read
Quality fundamentals and an attractive price line up (~357% below fair value) — the rarer case where both the business and the entry look good.
Aurinia Pharmaceuticals Inc. shows $283M in FY2025 revenue (+20.4% YoY), a 101.5% net margin, and 49.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $45.6M | $134M | $176M | $235M | $283M |
| Gross profit | — | — | — | — | — |
| Operating income | -$181M | -$111M | -$91.7M | -$4.69M | $105M |
| Net income | -$181M | -$108M | -$78.0M | $5.75M | $287M |
| Diluted EPS | -$1.40 | -$0.76 | -$0.54 | $0.04 | $2.07 |
| Net margin | -396.8% | -80.7% | -44.5% | 2.4% | 101.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.21B
EV / EBITDA17.8
EV / Sales7.8
EV / FCF—
P / FCF—
PEG (trailing)0.00
Earnings yield12.5%
FCF yield—
Quality & risk
ROIC (est.)14.3%
Free cash flow—
Total debt—
Net cash$80.2M
Altman Z-Score8.34 safe
Piotroski F-Score5/7
Capital returns
Buyback yield4.3%
Dividend yield (est.)—
Shareholder yield4.3%
Shares Δ YoY-3.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗4Period ending 2026-06-042026-06-08open ↗144Filing2026-06-05open ↗SCHEDULE 13D/AFiling2026-06-04open ↗8-KPeriod ending 2026-06-032026-06-04open ↗144Filing2026-06-04open ↗4Period ending 2026-05-292026-06-02open ↗144Filing2026-06-02open ↗4Period ending 2026-05-182026-05-20open ↗4Period ending 2026-05-182026-05-20open ↗
Frequently asked
- Is Aurinia Pharmaceuticals Inc. (AUPH) a buy?
- AUPH currently carries a Buy rating with 5/5 conviction, derived from its latest SEC filings. Revenue grew 20.4% YoY.
- What is AUPH's fair value?
- A Modified-Graham model based on AUPH's SEC fundamentals estimates a fair value of about $78.66. It is an estimate from reported earnings, not a price target.
- Is AUPH overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, AUPH currently appears undervalued relative to its SEC-grounded earnings power.
- What is Aurinia Pharmaceuticals Inc.'s quality score?
- AUPH scores 85.11764705882351/100 (grade A) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001600620, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:03:33 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.